Interviewer: Professor Holgate, thank you for taking the time to do this update on
the SNG001 drug as a COVID-19 therapy,
an inhaled formulation of interferon beta-1.
Could you summarise the key findings from
the phase 2 double-blind placebo-controlled trial,
which was completed since your last interview?
Prof. Holgate: Yes, thank you very much for inviting me to talk about this.
Just to summarise, once again,
this was a trial of
inhaled human interferon-beta given to patients admitted to hospital with COVID-19.
They received inhalation as
an aqueous aerosol daily for a period of
14 days, and then we followed them up for another 14 days,
totalling 28 days in all.
We had a number of endpoints.
This was an exploratory phase 2 trial, as you said.
We had 50 patients in each group, active versus placebo.
When we finally analysed the results at 28 days
(two weeks after the treatment had stopped),
we had some remarkable findings.
I think the most impressive finding was the rate of recovery back to normal,
normal functioning, being able to do things in life that you would normally do.
We showed that patients who had received the active treatment had about
a two- to three-fold increase in the rate of full recovery, compared to placebo.
That was quite a surprise,
especially when we looked at a sub-analysis that
looked at recovery on patients taking oxygen at baseline,